Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus

Código QR

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus

Shannon A Miller1, Erin L St Onge2, J Roger Accardi31Pharmacotherapy Faculty, Florida Hospital East Family Practice Residency, Orlando, Florida, USA; 2University of Florida College of Pharmacy, Orlando Campus, Florida, USA; 3Accardi Clinical Pharmacy, Orange City, Florida, USAAbstract: The American...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shannon A Miller, Erin L St Onge, J Roger Accardi
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/4a731fcf1dd7442caac8af79d6fa60ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Jonathan K Reynolds
Publicado: (2009)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto S, et al.
Publicado: (2015)

Clinical utility of fixed combinations of sitagliptin&ndash;metformin in treatment of type 2 diabetes
por: Karen Barnard, et al.
Publicado: (2010)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahr&eacute;n
Publicado: (2010)

Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
por: Stolar MW, et al.
Publicado: (2013)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Green J, et al.
Publicado: (2010)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holl, et al.
Publicado: (2014)

Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
por: Konya H, et al.
Publicado: (2013)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Stanley Schwartz, et al.
Publicado: (2010)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen AB, et al.
Publicado: (2013)

Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
por: Irons BK, et al.
Publicado: (2014)

Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage [Corrigendum]
por: Wilke T, et al.
Publicado: (2019)

Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated [Corrigendum]
por: Irons BK, et al.
Publicado: (2017)

Long-term (52&ndash;78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients
por: Bays HE
Publicado: (2012)

Sexual dysfunction in diabetic women: prevalence and differences in type 1 and type 2 diabetes mellitus
por: Mazzilli R, et al.
Publicado: (2015)

Recent results of exenatide use as adjunctive therapy in the treatment of patients with type 2 diabetes
por: Peggy Soule Odegard, et al.
Publicado: (2009)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Pamela Kushner
Publicado: (2010)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahren B
Publicado: (2010)

Sitagliptin Increases Beta-Cell Function and Decreases Insulin Resistance in Newly Diagnosed Vietnamese Patients with Type 2 Diabetes Mellitus
por: Le TD, et al.
Publicado: (2020)

Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus
por: Feher M, et al.
Publicado: (2013)

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
por: Maffioli P, et al.
Publicado: (2011)

Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
por: Fleming JW, et al.
Publicado: (2015)

Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
por: Lorber D
Publicado: (2014)

Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention
por: Alaa Badawi, et al.
Publicado: (2010)

Fixed combination of repaglinide and metformin in the management of type 2 diabetes
por: Robert Moses
Publicado: (2009)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Jason Seewoodhary, et al.
Publicado: (2010)

Holistic approach to prevention and management of type 2 diabetes mellitus in a family setting
por: Ofori SN, et al.
Publicado: (2014)

Management of gestational diabetes mellitus
por: Annunziata Lapolla, et al.
Publicado: (2009)

Evidence for the benefit of exercise therapy in patients with type 2 diabetes
por: Madden KM
Publicado: (2013)

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
por: Whaley JM, et al.
Publicado: (2012)

Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements
por: Yang F, et al.
Publicado: (2015)

Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management
por: Nitzan O, et al.
Publicado: (2015)

Mechanism linking diabetes mellitus and obesity
por: Al-Goblan AS, et al.
Publicado: (2014)

Risk management in the treatment of type 2 diabetes with pioglitazone
por: Giuseppe Derosa, et al.
Publicado: (2009)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
por: Rigato M, et al.
Publicado: (2014)

Importance of family/social support and impact on adherence to diabetic therapy
por: Miller TA, et al.
Publicado: (2013)

Pioglitazone improves the cardio-ankle vascular index in patients with type 2 diabetes mellitus treated with metformin
por: Ohira M, et al.
Publicado: (2014)

Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
por: Scott D
Publicado: (2013)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander PA
Publicado: (2012)

Using the health action process approach to predict and improve health outcomes in individuals with type 2 diabetes mellitus
por: MacPhail M, et al.
Publicado: (2014)